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Prostate cancer is the second most common cause of cancer deaths among males in the United States. Prostate screening by digital
rectalexamination andprostate-speciﬁcantigenhasshiftedthediagnosisofprostatecancertolowergrade,organconﬁneddisease,
adding to overdetection and overtreatment of prostate cancer. The new challenge is in diﬀerentiating clinically relevant tumors
from ones that may otherwise never have become evident if not for screening. The rapid evolution of imaging modalities and
the synthesis of anatomic, functional, and molecular data allow for improved detection and characterization of prostate cancer.
However, the appropriate use of imaging is diﬃcult to deﬁne, as many controversial studies regarding each of the modalities
and their utilities can be found in the literature. Clinical practice patterns have been slow to adopt many of these advances as a
result. This review discusses the more established imaging techniques, including Ultrasonography, Magnetic Resonance Imaging,
MR Spectroscopy, Computed Tomography, and Positron Emission Tomography. We also review several promising techniques
on the horizon, including Dynamic Contrast-Enhanced MRI, Diﬀuse-Weighted Imaging, Superparamagnetic Nanoparticles, and
Radionuclide Scintigraphy.
Copyright © 2009 A. H. Hou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Prostate cancer is the second most common cause of cancer
deaths among males in the United States. The incidence
of prostate cancer is relatively constant at 165 cases per
100,000 men. Since 1990, the age-adjusted death rate has
progressively decreased by 31%, which is attributed to early
detectionandtreatment[1].Prostatescreeningbydigitalrec-
tal examination (DRE) and prostate-speciﬁc antigen (PSA)
has shifted the diagnosis of prostate cancer to lower grade,
organ conﬁned disease [2, 3], adding to overdetection and
overtreatmentofprostatecancerbyatleast30%[4].Arecent
review by Etzioni et al. estimated that 10% of men with low-
grade prostate cancer were overtreated with radical surgery,
and 45% were overtreated with radiation therapy [5]. With
the publication of the 10-year results of the Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial
demonstrating no reduction of mortality with screening, the
new challenge is in diﬀerentiating clinically relevant tumors
from ones that may otherwise never have become evident if
not for screening [6].
The rapid evolution of imaging modalities allows
for better detection and staging of prostate cancer, thus
directing appropriate treatment and follow-up. However,
the appropriate use of imaging is diﬃcult to deﬁne, as
many controversial studies regarding each of the modal-
ities and their utilities can be found in the literature.
Here, we will discuss the more established imaging tech-
niques, and will review several promising techniques on the
horizon.
2.TransrectalUltrasound
2.1. Grey-Scale Ultrasound. Grey-scale transrectal ultra-
sound (TRUS) is the most commonly used modality for
evaluating the prostate, particularly for guiding needle
biopsies. When prostate cancer is suspected due to an
elevated PSA or an abnormal digital rectal exam (DRE),
the next step is usually a systematic needle biopsy, for
which TRUS is integral and eﬀective in identifying the
outlines of the prostate in sagittal and transverse planes. It is2 Advances in Urology
a simple and readily available modality, and can provide
fairly accurate estimations of the prostate volume which
are important in the determination of PSA density [7].
Prostate cancers typically appear hypoechoic on TRUS [8],
and hypoechoic lesions on TRUS are more than twice as
likely to contain cancer as isoechoic areas [9]. However,
most hypoechoic lesions found on TRUS are not cancer
[10]. Moreover, up to 30% of prostate cancers are isoechoic
[11],andapproximately1%arehyperechoic[8].Thepositive
predictive value (PPV) of grey-scale TRUS is reported to be
52.7%, and the negative predictive value (NPV) is 72%, with
anaccuracyof67%[12].Thus,itsutilityinthedetectionand
localizationofprostatecancerissomewhatlimited.However,
itremainstheimagingmodalityofchoiceforguidedprostate
biopsies, as well as for directing brachtherapy, cryotherapy,
high-intensity focal ultrasound ablation, and other locally-
directed therapies including hyperthermia, photodynamic
therapy, tumor vaccines, and gene therapy [13].
The value of TRUS for local staging is controver-
sial, although several studies have established criteria for
distinguishing extracapsular extension (ECE) on TRUS,
including bulging or irregularity of the capsule adjacent to
ah y p o e c h o i cl e s i o n[ 13], as well as length of contact of
a lesion with the capsule [14]. A multiinstitutional study
found TRUS to be no more accurate than DRE for the
purpose of detecting local tumor extension [15], although
other early reports found an increased accuracy when
ultrasound ﬁndings were combined with DRE and PSA
level [16]. Other studies have also found poor pathologic
correlation and inaccurate prediction of clinical stage with
TRUS and have shown that impalpable tumors have similar
outcomes regardless of TRUS ﬁndings [17, 18]. However, a
more recent study of 620 men who underwent TRUS by a
singleultrasonographerpriortoradicalprostatectomyfound
that evidence of extra-capsular extension (ECE) by TRUS
correlated with a signiﬁcantly higher pathologic stage [19].
They found that TRUS staging was the most signiﬁcant
predictor of ECE compared with established risk factors such
as Gleason grade and serum PSA, and furthermore that
TRUS staging performed as well as these other variables in
predicting biochemical failure after radical prostatectomy.
This study was performed at a single institution by a single
highly experienced ultrasonographer, and has yet to be
replicated in other reports.
2.2. Contrast-Enhanced Ultrasound. Interest in increasing
the sensitivity of ultrasound has led to the development of
multiple techniques based on ultrasound but incorporating
additional technology. Contrast enhanced TRUS (CEUS)
combines the value of traditional ultrasound in spatial and
temporal visualization of the prostate with the observa-
tion that the process of prostatic tumor growth induces
neovascularization [20]. CEUS is a method of measuring
the intraprostatic vascular structures using microbubbles
as the contrast agent. 1–10µm gas-encapsulating spheres
(microbubbles) are injected into the bloodstream, and
then visualized as they ﬂow through the prostate using
a transrectal ultrasound probe. The bubbles function as
additional reﬂectors to increase the sensitivity of color and
power Doppler [21]. Abnormal ﬁndings on CEUS have been
found to correlate with cancer on pathologic examination
[22].
In the early days of CEUS, when high-energy ultra-
sonography was used, the majority of the microbubbles were
destroyed by the pulsations, hindering visualization of the
microvasculature [23]. In recent years, several developments
in the technology have led to increased sensitivity of
microbubble visualization in the microvasculature of the
prostate. Wink etal. recentlyevaluatedtheresultsofmultiple
European studies which correlated CEUS and histology
ﬁndings on prostate resection, and concluded that tumor
localization using CEUS is a promising technique. The data
supports the use of CEUS in aiding in visualization of
prostatecancer,butthesensitivityandspeciﬁcityarenothigh
enough to justify discontinuing systematic prostate biopsies
[21].
Using contrast enhanced-ultrasound to target biopsies
has been found to detect statistically signiﬁcantly more
cancers with fewer number of cores compared to traditional
gray-scale ultrasound-guided biopsy [24] .T h es a m es t u d y
found a 2.6 fold higher likelihood of detecting prostate can-
cer when contrast-enhanced ultrasound was used, over gray-
scale ultrasonography. A study from the Netherlands [25]
examined how well was three-dimensional color-enhanced
power Doppler ultrasound (3D-CE-PDU)-directed prostate
biopsies compared with radical prostatectomy specimens.
All patients in the study were known to have prostate
cancer and were already scheduled for radical prostatectomy.
Overall, 51% to 63% of the prostate cancers were detected by
contrast-enhancedultrasound.Therewasahighersensitivity
(68%–79%) for detecting cancers with a maximum diameter
of ≥5mm. Of note, the study found only 13% of extracapsu-
lar extension or seminal vesicle invasion, demonstrating that
3D-CE-PDU is a poor tool for staging.
2.3. Elastography. Another approach based on TRUS is
elastography, which measures the rigidity and elastic prop-
erties of the prostate. The prostate is compressed using the
transrectal probe, and the diﬀerences in tissue strain are
used to localize intraprostatic lesions. Similar to the digital
rectal exam, areas of increased ﬁrmness are more suspicious
for malignancy. Pallwein et al. [26]f o u n das e n s i t i v i t y
and speciﬁcity of 87% and 92% for detecting prostate
cancer foci in a study of 15 patients who underwent real-
time elastography with subsequent radical prostatectomies.
They detected 28 of 35 tumor foci, with highest sensitivity
(100%) for detecting cancer at the apex. In another study
of 137 men who underwent targeted prostate biopsies
with elastography with color Doppler, an odds ratio of
1.82 was found, with a signiﬁcantly higher likelihood of
cancer detection than with gray-scale sextant biopsy [27]. A
greaterthantwo-foldincreasedlikelihood ofmalignancywas
noted in association with ultrasonic abnormality; abnormal
color ﬂow was associated with Gleason 8–10 (OR 4.12–
10.61). This association was not found in lower-grade
lesionswithcolorDoppler.However,abnormalelastographic
ﬁndings were associated with malignancy for all tumor
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In 2008, Salomon et al. [28]r e p o r t e do nap r o s p e c t i v e
single institution study of 109 men who were scheduled
for radical prostatectomy and underwent ultrasound-based
elastography-directed prostate biopsy. The PPV between
suspicious areas on elastography and cancerous areas found
on pathologic examination after radical prostatectomy was
87.8%, and the NPV was 59%. The sensitivity and speciﬁcity
of elastography in detecting cancer were 75.4% and 76.7%
respectively. Speciﬁcity increased to 80% when the lesion
was ≥5mm in diameter. Another study of 107 men with
PSA > 4ng/mL or abnormal digital rectal examinations
who underwent elastographic studies, regular transrectal
ultrasound, and power Doppler ultrasonography, found
the sensitivity of elastrography to be similar to that of
power Doppler (68% versus 70%) and higher than regular
ultrasound (50%), with a speciﬁcity of 81% [29]. Overall,
elastography seems to be a feasible, reproducible tool with
fairly good sensitivity for detecting prostate cancer. Further
clinical studies to clarify the role of elastography in the
detection of prostate cancer and its use in guiding prostate
biopsies are ongoing.
2.4. Computer-Aided Ultrasonography. Computer-aided ul-
trasonography, also known as HistoScanning, allows map-
ping of prostatic morphology, and identiﬁcation of malig-
nant lesions by characterizing and quantifying the disorga-
nization of the tissue. Theoretically, malignancy will induce
disorganization, and computer-aided ultrasonography will
detectthesechangesbyextractingthisdatafrombackground
ultrasonographic data. In a study of 29 patients who
underwentradicalprostatectomyafterHistoscanning,aclose
correlation between prostate HistoScanning analysis and
pathologic ﬁndings was found. The test was capable of
localizing tumors and determining their cross-sectional size
with fairly good accuracy, as well as identifying multifocality,
bilaterality, and extraprostatic extension. The authors of
the study propose that HistoScanning is an inexpensive,
noninvasive test with reasonable accuracy that could further
guide clinical decision making when it comes to selecting
m e nw i t hh i g hP S A st ou n d e r g op r o s t a t eb i o p s y[ 30].
However, further studies to validate this data are lacking.
3.MagneticResonance Imaging
3.1. T2-Weighted Magnetic Resonance Imaging. T h er o l eo f
standard T2-weighted MRI in the diagnosis and staging
of prostate cancer is still evolving and varies from center
to center. Generally, MRI has a fairly good sensitivity
but poor speciﬁcity [31–33]. A recent meta-analysis of
studies correlating MRI and histopathology found reported
sensitivities between 37% and 96% for detecting prostate
cancer, with diﬀerences due to variable deﬁnitions of cancer,
exclusion of transitional zone cancers, and criteria used for
positiveﬁndings[34].Speciﬁcityrangedfrom21%to67%in
this meta-analysis, although the authors note that speciﬁcity
is diﬃcult to assess due to inherent group selection bias in
these studies.
The speciﬁcity of MRI is decreased by its inability to
distinguish the low T2 signal intensity that is associated with
tumor from other pathologies such as prostatitis, postbiopsy
hemorrhage, or treatment changes [35]. Generally, a delay
of three to four weeks between prostate biopsy and MRI
was recommended [36, 37], although a more recent study
recommendedadelayofsixtoeightweekswhenmorebiopsy
cores are taken due to a higher degree of hemorrhage [38].
Detection of prostate cancer in the transitional zone was
thought to be inferior. A study by Ellis et al. found that MRI
missed78of79tumorsintheanteriorglandthatwere>5mL
in volume, although this study was done without the use of
endorectalMRI[39].OtherstudieshaveshownthatMRIhas
roughly equal accuracy throughout the prostate [35],a n d
that MRI has good sensitivity and speciﬁcity (75% and 87%)
in detecting transitional-zone cancers as well [40]. Akin et
al. [40] suggested that several indicators of transitional zone
cancer include homogenous low signal, lenticular shape, and
invasion of the anterior ﬁbromuscular stroma.
3.1.1. Screening. Many possible applications of MRI have
been proposed and studied. Some argue that it can con-
tribute to the screening process. In patients with a positive
PSA screening test but a negative biopsy, a negative MRI
result may eliminate the need for repeat biopsy by increasing
the NPV of a negative prostate biopsy. In a screening popula-
tionof92patients,Comet-Batlleetal.demonstratedanNPV
for cancer on subsequent transrectal biopsy of 91% [41],
which is comparable to the 85% NPV of a negative octant
biopsy [42]. Cheikh et al. reported an 82.6% sensitivity and
100% NPV of T2-weighted or dynamic contrast-enhanced
MRI when evaluating visible suspicious areas prior to repeat
TRUS prostate needle biopsy [43]. Beyersdroﬀ et al. studied
a population of 44 men who had elevated PSA but negative
initialbiopsy,andfoundthatinretrospectiveanalysisofMRI
after a repeat biopsy was performed, MRI imaging results
did not correlate with biopsy ﬁndings [31]. To the authors,
this conﬁrmed that MRI has a fairly low speciﬁcity and is
subject to error due to prostatitis, ﬁbrosis, or intraepithelial
neoplasia. The widespread use of MRI for screening pur-
poses has not been implemented despite several promising
studies, largely due to the high costs, although its use in
selected patients may be warranted after negative prostate
biopsies.
3.1.2. MRI-Guided Prostate Biopsy. The use of MRI to
guide prostate biopsies has also been proposed and is
currently under investigation and development. Beyersdroﬀ
et al. published reports of successful MRI-guided prostate
biopsy, noting that the technique was time-consuming and
required speciﬁc equipment, and was very susceptible to
prostate movement during biopsy [44] .M u l t i p l eg r o u p sa r e
experimenting with needle-positioning devises and robotic
manipulators to facilitate MRI-guided biopsies [45]. How-
ever, routine use of MRI to guide prostate biopsy is not
recommended with existing evidence, due to expense and
the time-consuming nature; although with further develop-
ments and experience, there may be indications for MRI-
guided biopsies in patients with previous negative TRUS-
guided biopsies.4 Advances in Urology
3.1.3. Preoperative Assessment. Recently, MRI has been
evaluated for its utility in preoperative assessment prior
to prostatectomy. Hricak et al. found that by reviewing
preoperative endorectal MR images, surgeons were more
accurately able to decide whether or not to preserve the
neurovascular bundle during surgery [46]. 135 patients
were evaluated with MRI preoperatively and judged by a
surgeon and radiologist, then compared to surgeon’s clinical
judgement during surgery and to histopathologic ﬁndings.
TheyfoundthatwhenthesurgeondecidedtosparetheNVB,
MRIconﬁrmedthatdecisionin84%ofcases,andwascorrect
in 96% of the time. MRI results changed the surgical plan
in 78% of high-risk patients (>75% risk of ECE on Partin
tables), and was correct in 93% of cases. These results were
supported by a recent study from Scandanavia of 75 patients,
which showed a sensitivity of 92% and speciﬁcity of 100%
for detection of ECE/NVB involvement with preoperative
MRI [47]. MRI ﬁndings favored NVB preservation in 67% of
patientswithahigh-clinicalprobabilityofECE,andopposed
NVB preservation in 33% of patients with low probability,
and was correct in 100% of the time. Another series showed
that prominence of apical periprostatic veins on preop-
erative endorectal MRI was signiﬁcantly associated with
intraoperative blood loss [48]. These studies support the
use of MRI for preoperatively assessing patients, particularly
regarding the decision to spare or resect the neurovascular
bundles.
3.1.4. Staging. Due to many advances in technology, MRI
is now considered by many to be the most exact imaging
modality for staging prostate cancer, including pelvic lymph
node and pelvic bony metastases [49–53], although studies
have found that there is signiﬁcant intraobserver variability
in the use of MRI for detecting prostate cancer [54].
Several early studies found that the sensitivity of MRI
in detecting extra-capsular extension was limited [55–57];
however, developments in technology have improved the
accuracyforlocalstaging.Theuseofendorectal-bodyphased
array coils, as opposed to a torso phases-array coils, has
been shown to oﬀer superior staging accuracy [58]. This
techniqueimprovesthespatialresolutionandsignal-to-noise
ratio of prostate MRI [31]. Endorectal MRI has been found
tohavehighnegativeandpositivepredictivevalues,aswellas
good accuracy in predicting extracapsular invasion [58, 59].
Two meta-analyses of staging accuracy with endorectal MRI
have been conducted, with diﬀering results; one found that
endorectalMRIimprovedstagingperformance[60],whereas
the other found the opposite [61].
Other recent developments have improved the accuracy
of T2-weighted MRI in local staging as well, including faster
imaging sequences, postprocessing image correction, and
more powerful coils [58, 62, 63]. The use of persextant
localization is another development in MRI technology that
has allowed more eﬃcient communication of data [35,
64]. Theoretically, a 3Tesla endorectal coil should provide
improved signal-to-noise ratio and improve image quality,
and several early reports do report signiﬁcantly improved
staging performance, with sensitivities of 73–88% and
speciﬁcities of 96–100% [65, 66]. However, this technology
is not widely available, and more studies are needed before
widespread implementation.
Despite these technological advances, the use of MRI for
staging prostate cancer is still fairly controversial, and its use
at diﬀerent institutions is still evolving. Several studies have
focused on the utility of MRI across diﬀerent risk groups in
an attempt to solve the issue of which patient population
should undergo preoperative MRI for staging. It has been
found that the inclusion of MRI in clinical nomograms
increases the prediction of local tumor extent in all risk
groups[67].Engelbrechtetal.havesuggestedthatinpatients
with an intermediate risk of having stage T3 disease, as
predicted by having a PSA of 4–20ng/mL and a Gleason
score between 5 and 7, MRI is advised because the treatment
decisionmaydependonimagingresults[68].Anothergroup
found that 26% of low-risk patients, with PSA < 10ng/mL
and Gleason 2–7 or PSA 10.1–20ng/mL and Gleason 2–5,
had histopathologic proof of ECE or SVI seen on MRI prior
to surgery [63], which may indicate justiﬁcation of routine
MRI in this group as well. Furthermore, The American Joint
Commission on Cancer currently recommends either CT or
MRI in the high-risk group, with PSA > 20 or Gleason > 7-8
[69].
Those who argue against its routine use in preoperative
evaluation cite its expense and questionable utility. D’Amico
et al. suggested that although MRI does increase the pre-
diction of biochemical failure in a signiﬁcant number of
patients, the high cost of routine use of MRI is not justiﬁed
in light of questionable eﬀect on decreasing unnecessary
surgeries [70]. Another study by May et al. evaluating at the
ability of endorectal MRI to detect and stage prostate cancer
concluded that due to poor sensitivity and speciﬁcity, high
intraobserver variability, and a tendency to overstage cancer,
MRI results should not result in alteration of treatment
decisions [71].
3.2. Magnetic Resonance Spectroscopic Imaging. Intrapro-
static tumor growth is associated with increased cell mem-
brane turnover and increased cell proliferation, which lead
to altered relative concentrations of certain metabolites
including creatine, choline, and citrate, most speciﬁcally
an increase in choline and a decrease in citrate. Magnetic
resonancespectroscopy(MRSI)isatechnologythatincreases
the sensitivity and speciﬁcity of MRI by analyzing this
metabolic proﬁle of discreet voxels within the prostate [72,
73]. The largest study comparing MRSI to MRI, by Wefer
et al., found that MRSI alone had a higher sensitivity
(76%) than T2-weighted MRI (67%), but a lower speciﬁcity.
However, this and other studies have found that the accuracy
in diagnosing prostate cancer is the highest when anatomic
information from MRI and metabolic information from
MRSI are combined [35, 72, 74]. Another study combined
data from MRI/MRSI with clinical and pathological data,
and found that a combined model was superior to purely
clinical models at predicting the probability of insigniﬁcant
prostate cancer [75].
More recently, several studies have analyzed the eﬀects of
adding data from MRI/MRSI to the staging normograms. In
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underwent combined MRI/MRSI prior to radical prostate-
ctomy, the radiologic ﬁndings contributed signiﬁcant value
to the standard normogram for predicting prostate-conﬁned
disease [67].
Spectroscopy has several other advantages over tradi-
tional MRI. The ability of MRSI to detect transition zone
tumors has been reported to be 80%, signiﬁcantly higher
than T2-weighted MRI [40]. Coakley et al. [76] explored the
abilityofMRSItoestimatethevolumeofprostatecancer,and
found improved accuracy in volume measurements when
spectroscopy is added to MRI. Yu et al. also demonstrated
that use of spectroscopic imaging decreases interobserver
variability, and for less experienced radiologists, improved
the detection of ECE [49].
A recent multiinstitutional study of 134 men with
biopsy-proven prostate cancer who underwent combined
MRSI/MRI found somewhat disheartening results [77].
When compared to endorectal MRI, combined MRSI/MRI
showed no demonstrable beneﬁt. This study was speciﬁcally
conductedwithinexperiencedoperators,andwasfocusedon
low-risk patients with small disease burden, representative of
the screened American population.
3.2.1. Tumor Aggressiveness. MRSI has potential as a nonin-
vasive method of assessing tumor aggressiveness, as it has a
higher sensitivity in detecting cancers of higher grade [78].
Zakian et al. studied the relationship between Gleason grade
as a measure of tumor aggressiveness and MRSI volumetric
and metabolic data, and found that the ratio of creatine
plus choline to citrate, which is a ratio that is known to
be positively correlated with prostate cancer, can predict the
aggressiveness of the tumor. This study also found that MRSI
detected only 44% of Gleason 3 + 3 tumors, compared to
90% of Gleason >7 cancers. Thus, spectroscopic information
may contribute to the decision-making process by providing
information about tumor aggressiveness.
3.2.2. Additional Uses. Additional uses of MRSI in prostate
cancer have been proposed, including supplementing biop-
sies as a method of detecting both primary and recurrent
cancers [34, 35], and as a tool to guide biopsies [79, 80].
Due to the higher sensitivity of MRSI in detecting cancer
than sextant biopsies, especially when localized to the apex
where biopsies may not sample [35], it may be an adequate
method of following patients who have undergone ablative
therapy. One study found that MRSI detected all recurrent
foci of tumor in 25 patients who had undergone cryotherapy
for prostate cancer [81]. Another study of 9 patients with
recurrent prostate cancer after external beam radiation
therapy found that MRSI and MRI were both superior
to biopsy at detecting recurrent disease, with sensitivities
of 77% and 68%, respectively [79]. However, they also
found that the speciﬁcity of MRSI (78%) was signiﬁcantly
lower than regular MRI, DRE, or sextant biopsy, which
was attributed to postradiation metabolic changes in the
normal prostate. The authors suggested that MRSI may be
used to supplement other techniques to detect recurrent
cancer, to guide biopsies, or to guide treatment by providing
localization of tumor [79].
3.3. Dynamic Contrast-Enhanced MRI. Dynamic contrast-
enhanced-MRI (DCE-MRI) measures the vascularity of
prostatic tissue using temporal diﬀerences in the uptake of
intravenously-administered low molecular weight contrast
to distinguish between benign tissue and tumor. Increased
microvessel density is seen in BPH, prostatic intraepithelial
neoplasia, and prostate cancer [82], and has been found to
correlate with disease-speciﬁc survival and progression after
treatment [83]. Several microvascular features are charac-
teristics of prostate cancer, including heterogenic structure,
arterio-venous shunting, vascular tortuosity, intermittent
ﬂow, high permeability, and poorly formed vessels [82].
Using various MR sequences, especially T1-weighting [84],
these characteristics can be visualized and quantiﬁed.
The use of DCE-MRI for primary detection, localization,
and staging of prostate cancer has been studied by several
groups,withpromisingresults.Jageretal.initiallyfoundthat
the use of DCE-MRI increased the sensitivity for detecting
prostate from 57% with T2-weighted MRI to 73%, with
no change in speciﬁcity [85]. They also noted that DCE-
MRI may improve sensitivity for detecting ECE, and that
this technology may improve estimations of tumor volume.
Other studies have conﬁrmed that DCE adds signiﬁcantly
to the sensitivity for detecting prostate cancer over other
modalities [86–89] and that it is fairly accurate in detecting
ECE [90, 91]. A recent prospective study found that DCE-
MRIhadhigherlocalizationaccuracythanT2-weightedMRI
or MRSI in both the central and peripheral glands [92].
When compared to transrectal power-dopper ultrasound,
DCE-MRI was found to be signiﬁcantly more sensitive for
detecting cancer in the peripheral zone [89]. Namimoto et
al. conﬁrmed that DCE-MRI is useful in the diﬀerentiation
of peripheral-zone lesions, and also found higher diagnostic
accuracy when dynamic MR results were combined with
postcontrast T1-weighted images [93]. Other proposed uses
for DCE-MRI that include detection of recurrence and
follow-up after ablative therapy or androgen deprivation
[82].
There is a potential for DCE to predict pathologic grade
of prostate cancer, given that microvessel density has been
found to correlate with Gleason score [94, 95]. Schlemmer
et al. noted that time to onset of the enhancement curve
was signiﬁcantly diﬀerent in high-grade tumors compared
to low-grade tumors [86]. Another study using pathologic
specimens for correlation did not ﬁnd any correlation
between enhancement times and pathologic grade [96].
Kim and Park speculated that DCE-MRI may beneﬁt
immensely from the advent and institution of 3 Tesla due
to increased signal-to-noise ratio and because of the T1
properties of prostate tissue [97]. An early study found that
at 3 Tesla, DCE-MRI has a higher accuracy and sensitivity,
although a lower speciﬁcity, than T2-weighted imagining,
and concluded that DCE-MRI may thus be more useful for
diagnosis and preoperative staging [51]. F¨ utterer et al. found
that DCE-MRI at 3 Tesla was superior to 1.5 Tesla in regards
to delineation of prostate cancer, extra-capsular extension,
and visualization of the peripheral zone and central zone
[98]. They found an overall staging accuracy of 83% at 1.5
Tesla, and 100% at 3 Tesla.6 Advances in Urology
It is clear that more studies are needed the deﬁne to
role of DCE-MRI in the evaluation of prostate cancer.
Major limitations of this technology include the inability to
diﬀerentiate between prostatitis and prostate cancer in the
peripheral zone and between BPH and cancer in the central
zone [99]. With current evidence, it has been proposed
that DCE-MRI can be used in combination with T2-
weighted MRI, MRSI, and DWI as part of an assessment of
cancer probability, to guide targeted rebiopsy [82], and to
preoperatively stage patients with prostate cancer [51, 91].
3.4. Diﬀusion-Weighted Imaging MRI. Diﬀusion-weighted
imaging (DWI) is a method of obtaining molecular and
cellularinformationabouttheprostate,speciﬁcallyregarding
the movement and functional environment of water in
prostate tissue. By measuring the microdiﬀusion of water in
the intracellular and extracellular spaces, DWI can calculate
an apparent diﬀusion coeﬃcient, which reﬂects compart-
mental shifts in water, membrane permeability, and cellular
density, all of which may be altered in cancerous tissue [100].
Prostate cancer has a lower apparent diﬀusion coeﬃcient
than does normal prostate tissue, both in the peripheral zone
[101] and in the transition zone [102], which indicates a
reduction in ﬂow or diﬀusion of water. This is attributed
primarilytoanincreaseincellularityinthistissue[101,102].
Several studies have analyzed the value of adding DWI
to T2-weighted MRI and MRSI, and have generally found
increased sensitivity (54%–98%) and speciﬁcity (58%–
100%) [100, 103, 104]. Kim et al. recently found that com-
bined DWI/T2WI is more sensitive for predicting recurrent
cancer after radiation therapy than T2WI alone [105]. DWI
has also been found to increase the accuracy of peripheral
zone tumor volume measurements [106]. Park et al. recently
reportedthatDWImaybeusefulintheevaluationofpatients
with persistently elevated PSA values but negative prostate
biopsies, as it was more sensitive than T2-weighted MRI in
localizing lesions [107].
Major limitations of this technology include a substantial
overlap of ADC values between malignant tissue and normal
prostate and a marginal signal-to-noise ratio [105]. Modern
3Tesla MRI systems are under investigation for their utility
in increasing signal-to-noise ratios for DWI. Early studies
with this technology report a high sensitivity (94%) and
speciﬁcity (91%) in the peripheral zone, and a similarly high
sensitivity (90%) and speciﬁcity (84%) in the transition zone
[108]. Future research will further elucidate the role of DWI
in the diagnosis and staging of prostate cancer, although
preliminary studies are very promising.
3.5. Superparamagnetic Nanoparticles. Another MRI-based
technology currently under active investigation is the use of
lymphotropic superparamagnetic nanoparticles as a contrast
agent to detect small and otherwise undetectable nodal
metastases. This material is injected intravenously and is
taken up by macrophages in normal lymph nodes, creating
a contrast between these nodes and cancerous nodes where
the macrophages have been replaced by tumor cells [109].
The technology does not rely on the size or shape of
the lymph node, criteria on which traditional radiographic
staging is based, and is thus suspected to be more accurate
in detecting metastases especially in normal-sized nodes. It
has been proven to be eﬀective in several other cancers [109].
Investigations into its use in prostate cancer are ongoing.
Harisinghani et al. found that lymphotropic nanoparticle-
enhanced MRI (LNMRI) can detect metastases in small
lymph nodes that would be considered benign on CT or
unenhanced MRI, and that metastatic nodes were found
outside of the classical ﬁeld of lymph node dissection in a
signiﬁcant number of patients [110]. This study evaluated
80 patients with LNMRI prior to either pelvic lymphadec-
tomy or diagnosis of metastases with CT, and found that
the addition of superparamagnetic nanoparticles increased
sensitivity of MRI from 45.4% to 100% with a speciﬁcity of
95.7%. It has been suggested that this technology may be of
particular utility in patients who have high risk of metastatic
disease on the basis of standard staging nomograms and
conventional MRI, both of which oﬀer fairly high negative
predictive values for the detection of metastatic disease [13].
This technology may also be useful in detecting recurrent
cancer, as well as guiding targeted radiation therapy. A
recent study reported that in 26 patients with recurrent
prostate cancer after radical prostatectomy, all of whom were
candidates for salvage radiation therapy, LNMRI detected
positive nodes in 6 patients, none of whom had enlarged
nodes on axial imaging [111]. Further studies are needed
before this promising but experimental technology enters
wide-spread use.
4. Computed Tomography
Atthistime,CThasverylittleroleinthediagnosisofprostate
cancer or in staging of known cancers in patients with a low
clinicalsuspicionofmetastaticdisease[13].CTdetectsnodal
metastases based on size, and in general CT has a very low
diagnostic yield in low-risk patients due to a low incidence of
large nodal metastases in these patients. The primary role of
CTinprostatecancerisinstagingforpatientswithsuspected
metastatic disease, for which is has variable sensitivity and
speciﬁcity [112, 113]. O’Dowd et al. [114] recommend that
CT be used for high-risk patients with PSA > 20ng/mL,
Gleason score > 7, or at least clinical stage T3 disease.
For the purpose of detecting pelvic lymph node metastases,
the sensitivity has been reported from 25% [115] to 85%
[116], but is generally approximately 36% [117], which is
not suﬃciently accurate to justify widespread use except for
selected high-risk patients. Similarly, for diagnosing bone
metastases, CT is inferior to other modalities such as bone
scans and MRI, and should not be widely used [13].
5. Positron Emission Tomography
The theory behind positron emission tomography (PET)
is that prostate cancer, having a high metabolic rate, will
consume glucose through the glycolytic pathway, which is
associated with higher glucose uptake. PET uses a radi-
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(FDG), as a tracer to measure the metabolic rate of the
tissue, and attempts to identify cancerous lesions based on
their increased metabolism. Despite initial enthusiasm for
PET as a diagnostic modality for prostate cancer, studies
have shown mediocre results, with suboptimal sensitivity
[118, 119]. Eﬀert et al. found that they were unable to
diﬀerentiate between primary prostate cancer and benign
prostatic hypertrophy with FDG PET [120], as both exhibit
increased metabolism. This is thought to be due to a lower
rate of growth and thus lower level of radiotracer uptake by
prostate cancers than by other cancers in the body for which
P E Th a sb e e nf o u n dt ob em o r eu s e f u l[ 121]. Moreover, as
FDG is excreted by the kidneys, it tends to accumulate in
the bladder and the prostatic urethra, thus masking uptake
by the prostate [121]. Even when this was compensated for
by diuresis with furosemide prior to PET scan [122]o r
continuous bladder irrigation, sensitivity was not suﬃcient
to reliably detect prostate cancer or for the detection of
lymph node metastases [123].
Other radiotracers with diﬀerent properties are being
investigated. Several studies have used 11Carbon- and
18Fluoride-based agents, including 11Carbon-methionine,
18F-Fluorocholine, 11Carbon-choline, and 11Carbon-acetate,
as tracers for detecting prostate cancer. These tracers are
radiolabeled amino acids which are concentrated in lesions
with high protein synthesis rates, and can theoretically be
used to identify cancerous lesions. They are used in the
diagnosis of many diﬀerent cancers, with sound clinical
background, and are undergoing further testing for use in
the primary diagnosis of prostate cancer, with limited utility
at this point due to inadequate accuracy [72, 124–126].
Moreover, due to rapid decay of 11Carbon, the use of these
agents necessitates a local cyclotron, limiting its widespread
availability.
Several studies have evaluated the use of PET for the
staging of prostate cancer. Schiavina et al. [127] found that
11C-choline PET performed better than clinical nomograms
for predicting nodal metastases, with a sensitivity and
speciﬁcity of 60% and 98%. Results from a study by Husarik
at al. [128] found more discouraging staging accuracy with
18F-FCH PET, with only one in ﬁve histopathologically-
conﬁrmed metastatic lymph nodes detected by imaging.
The most promising results with PET/CT are in the
ﬁeld of detecting recurrent disease after primary therapy
for prostate cancer [129]. Rinnab et al. found ﬁrst that
11C-choline was useful for targeted salvage lymph node
dissection after treatment for prostate cancer [130], and then
more recently that 11C-choline has a high sensitivity (93%)
and PPV (80%) for detecting local recurrence or distant
metastases [131]. This more recent study conﬁrmed the
results of several previous studies [132, 133] that PET/CT
using 11C-cholinemaybeausefulapproachfordetectingand
localizing recurrent disease, but also showed that integrated
PET/CT systems may be particularly helpful at low PSA
levels.
The future of PET/CT in the ﬁeld of prostate cancer is
bright, with many developments on the horizon, from new
tracers and technology to novel reading techniques. Li et al.
recently reported that using a ratio of uptake values between
prostate tissue and muscle as a primary measurement, 11C-
choline PET achieved a sensitivity and speciﬁcity of 90%
and 86%, may be a feasible technique to diﬀerentiate benign
from malignant prostate lesions. Nu˜ nez has proposed a
combined use of FDG and 11C-methionine based on a
temporalcascadeofmetabolicactivity,withincreaseduptake
of 11C-methionine in the early stages of cancer followed
by relatively higher uptake of FDG during more advanced
cancer stages [134]. Another group recently reported on the
combined use of 11C-Choline and FDG for the detection
of cancer after biochemical recurrence, and reported a
sensitivity of 80% when a PSA cutoﬀ of 1.9ng/mL was used
[135]. Hricak et al. suggested that novel iterative imagine
reconstruction techniques will help to reduce artifact [13].
Several groups are also looking at new radiotracers that
incorporate antibodies targeting molecules such as prostate-
speciﬁc membrane antigen, which may signiﬁcantly increase
speciﬁcity of PET/CT [136, 137].
6. Radionuclide Scintigraphy
Prostascint is an immunoscintigraphic diagnostic mode
utilizing [111] indium-capromab pendetide, a radiola-
beled murine monoclonal antibody that is reactive with
prostate-speciﬁc membrane antigen (PSMA), a glycoprotein
expressed by prostate tissue. Images are captured with a
SPECT gamma camera. It was approved by the FDA in 1996
for the detection of recurrent prostate cancer in soft tissue
[138], with a reported sensitivity and speciﬁcity of 62% and
72% [139]. Seltzer et al. compared helical CT, PET, and
Prostascint to evaluate for lymph node metastasis in patients
with PSA recurrence. They found that Prostascint had a
lower detection rate of metastatic disease than CT or PET
[140]. Nagda et al. [141] performed a retrospective review
of 58 patients who had rising PSA levels after prostatectomy
but negative CT-scans and underwent a capromab pendetide
scan. The PPV in detecting disease outside the prostate
was 27%. The PPV for detecting prostatic fossa recurrence
was 50%. Scan status was not found to be predictive of
worsened biochemical recurrence free survival, indicating
that decisions for adjuvant radiation therapy for biochemical
recurrence should not be based upon the ﬁndings of the
capromab study alone. Another study by Koontz et al.
likewise did not ﬁnd a diﬀerence in progression-free survival
in patients with biochemical recurrences depending on
ﬁndings of capromab scans. A major limitation of this
technology is that the antibody targets an epitope that is only
exposed by cancer cells that are dead or dying, which thus
limits its sensitivity [142, 143]. The use of capromab studies
varies from institution to institution, and more experience is
needed before recommendations are solidiﬁed.
7. Conclusion
We have described some of the recent advances in the ﬁeld
of imaging of prostate cancer, and highlighted some of the
many new technologies on the horizon that will further
enable rapid and eﬀective diagnosis, staging, and follow-
up of prostate cancer. With new modalities for visualizing8 Advances in Urology
prostate cancer, we are better than ever before able to
characterize and localize lesions, and we are learning how
to apply these capabilities to improved treatment decisions
and more eﬀe c t i v ef o l l o w - u p .T h e s ea d v a n c e sw i l lh o p e f u l l y
contribute to improved long-term outcomes.
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